旭輝(00884.HK)折讓12.3%先舊後新配股淨籌6.2億元 午後復牌
旭輝(00884.HK)公佈,公司主要股東、林氏家族信託全資持有的茂福投資作爲賣方,於8月31日與公司及配售代理訂立配售及認購協議。賣方將配售近3.05億股現有股份,相當於公司經擴大的已發行股份總數約3.23%,而旭輝已有條件地同意以等同配售價的認購價向賣方配發及發行等量新股份。
配售價爲每股2.06元,較上一個交易日收市價每股2.35元折讓約12.3%,所得款項總額預期將約爲6.28億元,預期所得淨額約6.23億元,將用於現有債務再融資及用作一般企業用途。
按公司的要求,其股份、債務證券、認股權證及衍生工具已於今日(31日)上午9時半起停牌,以待刊發本公告,已申請於今日下午1時起恢復買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.